Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193140 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
A Phase 2 study of Solid Tumor Cancers, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01193140 is a Phase 2 study of Solid Tumor Cancers that has completed, run by Abbott. The registered enrollment target is 24 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT01193140, a Phase 2 study of Solid Tumor Cancers, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG veliparib
Study Locations (2)
California
- Site Reference ID/Investigator# 43022 - Encinitas
- Site Reference ID/Investigator# 42662 - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193140
The ClinicalTrials.gov registry entry for NCT01193140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor Cancers appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT01193140 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01193140 about?
NCT01193140 is a clinical study titled "To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors". To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.
What is the current status of trial NCT01193140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-07. Estimated completion is 2011-11.
What conditions does trial NCT01193140 study?
This clinical trial studies the following conditions: Solid Tumor Cancers.
What interventions are being tested in trial NCT01193140?
The interventions under investigation include: Temozolomide (DRUG), veliparib (DRUG).
Who is sponsoring clinical trial NCT01193140?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01193140 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.